DKD. V. Kadomtsev

D. V. Kadomtsev

*This is an algorithmically generated author record based on publicly available information.

D. V. Kadomtsev has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epithelial Mesenchymal Transition Markers as Relevant Parameters for Risk Stratification of Poor Clinical Outcomes in Patients with Early-Stage Cutaneous Melanoma

    by E. A. Pasechnikova, D. V. Kadomtsev, V. A. Porhanov, S. D. Maksimenko

    Objective: To evaluate the prognostic significance of Epithelial Mesenchymal Transition (EMT) transition markers and their association with clinicopathological characteristics of cutaneous melanoma.Materials and Methods: Histopathological and immunohistochemical examination of primary tumor tissue samples was performed in 101 patients with cutaneous melanoma of stage pT1a–1b. The study evaluated the expression of E-cadherin, TWIST, vimentin, Ki-67, Melan-A, and S100 markers.Results: A significant correlation was identified between the expression of TWIST, vimentin, and E-cadherin and the depth of tumor invasion, primary tumor ulceration, and risk of progression. Disease progression was observed in patients with TWIST and vimentin expression levels > 20%, and E-cadherin expression < 80%. Ulceration of the skin was significantly associated with enhanced EMT features and a greater risk of metastatic dissemination.Conclusion: The analysis of the obtained results confirms the clinical significance of epithelial–mesenchymal transition markers as independent predictors of disease outcome, also emphasizes the key role of ulceration as an important morphological risk factor for disease progression. The proposed prognostic model, based on the assessment of relative expression levels of TWIST, vimentin, and E-cadherin, provides reliable classification of patients according to their risk of complication development.

  • Open Access

    The epithelial-to-mesenchymal transition in cancer: pathogenetic features

    by E. A. Pasechnikova, V. N. Bodnya, D. V. Kadomtsev, A. Yu. Georgieva, V. A. Porhanov, D. D. Shevchuk

    The epithelial‑to‑mesenchymal transition (EMT) is a cellular biological process, that occurs in a wide range of cells and tissues and is triggered by complex regulatory networks involving transcriptional control with SNAIL, ZEB1, ZEB2, Twist, SLUG, E‑cadherin, vimentin, tumor microenvironment and genetic characteristics. EMT is represented by the multi‑stage development and transformation of cells of the epithelial phenotype into cells that acquire mesenchymal features of various severity. These quasi‑mesenchymal cells are characterized by stemness, tumor heterogeneity, increasing invasiveness, drug resistance and a tendency to distant metastasis, which leads to the proliferation of neoplastic cells, tumor dissemination and initiation of metastasis, which induces the therapy resistance and the oncological recurrence.This review is based on the latest scientific publications about the EMT phenomenon, indexed in PubMed. The aim of the study was to evaluate the biochemical and molecular pathogenetic mechanisms of EMT and the effect of EMT markers on the progression of neoplastic processes and the effectiveness of the treatment. Nowadays the proper EMT scheme that combines all the molecular transformations of sells with quasi‑mesenchymal phenotype doesn’t exist. But analyzing the features of this cellular program, we can find the proper therapy, that could be able to suppress the plasticity of cancer cells, prevent EMT induction by blocking contextual signals, and induce mesenchymal‑epithelial transition. All these aspects will lead to the reduction of the risk of tumor dissemination and the increase of the effectiveness of cancer treatment.


  • Open Access

    Liquid biopsy: the current state of the issue

    by E. A. Pasechnikova, V. N. Bodnya, S. V. Sharov, D. V. Kadomtsev, A. Y. Georgieva, А. И. Стукань

    Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic changes. This work included a literature review of current scientific publications on liquid biopsy techniques indexed in PubMed.Objective The aim of the study was to evaluate the efficacy and peculiarities of this technique in comparison with standard methods of morphological verification of oncological diseases, as well as the feasibility of its use in clinical practice. Compared to tissue biopsy LB has the following advantages: simplicity and speed of examination, easy repeatability and low invasiveness, possibility of dynamic monitoring of tumor progression – general clonal transformation as well as the appearance of resistance to treatment. The disadvantages of this method include low sensitivity, difficulty in proper interpretation of biomarkers and determination of their specificity, high risk of false positive and false negative results due to the presence of dormant tumor cells.Conclusion Currently, liquid biopsy analysis in clinical practice requires standardization and continuous validation.